Teva to collaborate with Fosun Pharma for TEV-56278
The collaboration will enhance clinical data generation for the potential treatment.
Immuno
EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL
NICE approves GSK’s belantamab mafodotin for blood cancer
Antares Therapeutics gains $177m for cancer medicines development
ASH 2024: Regeneron’s Ordspono faces challenges, but positive results signal hope
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers
NCCN visits Vietnam in continued cancer care collaboration
Bladder cancer diagnoses to top 300,000 in major markets by 2033
